Managers / Q1 2026
Omega Fund Management, LLC
CIK 0001637359 · 888 BOYLSTON ST., SUITE 1111, BOSTON, MA, 02199 · 617 502 6538
Summary
Omega Fund Management, LLC reported $163M in U.S.-listed holdings across 10 positions for Q1 2026.
The portfolio is heavily concentrated: BCAX alone accounts for 29.2% of reported value.
Compared with Q4 2025, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 83.9% · $137M
- Other · 16.1% · $26M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| UPBUpstream Bio Inc. | SOLD OUT | −1.33M | 0 | −$36M | $0 |
| ALMSAlumis Inc. | TRIMMED | −412.0K | 241.3K | −$1M | $5M |
| Kestra Med Technologies Ltd | TRIMMED | −351.4K | 1.02M | −$16M | $20M |
| BCAXBicara Therapeutics Inc. | ADDED | +187.5K | 2.39M | +$10M | $48M |
| NUVBNuvation Bio Inc. | HELD | +0 | 8.08M | −$38M | $35M |
| BBNXBeta Bionics Inc. | HELD | +0 | 1.32M | −$27M | $13M |
| BBOTBridgeBio Oncology Therapeutics Inc. | HELD | +0 | 3.29M | −$12M | $29M |
| enGene Holdings Inc. | HELD | +0 | 876.4K | −$2M | $6M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BCAXBicara Therapeutics Inc.history → | Common Stock | 29.16% | $48M | 2.39M |
| 2 | NUVBNuvation Bio Inc.history → | Common Stock Class A | 21.25% | $35M | 8.08M |
| 3 | BBOTBridgeBio Oncology Therapeutics Inc.history → | Common Stock | 18.05% | $29M | 3.29M |
| 4 | Kestra Med Technologies Ltd | Common Stock | 12.49% | $20M | 1.02M |
| 5 | BBNXBeta Bionics Inc.history → | Common Stock | 8.08% | $13M | 1.32M |
| 6 | enGene Holdings Inc. | Common Stock | 3.66% | $6M | 876.4K |
| 7 | ALMSAlumis Inc.history → | Common Stock | 3.26% | $5M | 241.3K |
| 8 | SANASana Biotechnology, Inc.history → | Common Stock | 1.49% | $2M | 843.8K |
| 9 | IMAImageneBio, Inc.history → | Common Stock | 1.40% | $2M | 455.4K |
| 10 | REPLReplimune Grouphistory → | Common Stock | 1.17% | $2M | 248.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $163M | 10 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $287M | 11 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $222M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $154M | 13 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $169M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $121M | 11 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $160M | 11 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $135M | 11 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $155M | 11 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $123M | 14 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $109M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $178M | 12 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $153M | 14 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $297M | 16 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 19 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $313M | 21 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $489M | 22 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $707M | 22 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021REVEALED | $1.5B | 30 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $604M | 21 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $734M | 22 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $667M | 19 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $370M | 16 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $366M | 15 | Aug 17, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $242M | 16 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $314M | 14 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $324M | 14 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $392M | 15 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019REVEALED | $473M | 25 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $135M | 14 | Feb 11, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.